Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management options for thrombophilias.

Alexander S Gallus1

  • 1Flinders Medical Centre, Adelaide, South Australia, Australia. alexander.gallus@flinders.edu.au

Seminars in Thrombosis and Hemostasis
|February 12, 2005
PubMed
Summary

Thrombophilia management requires individualized assessment of thrombosis and bleeding risks. Inherited thrombophilias do not change anticoagulant intensity but may extend treatment duration for venous thromboembolism.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.

Thrombosis and haemostasis·2016
Same author

Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).

Thrombosis and haemostasis·2013
Same author

Oral apixaban for the treatment of acute venous thromboembolism.

The New England journal of medicine·2013
Same author

Apixaban for extended treatment of venous thromboembolism.

The New England journal of medicine·2012
Same author

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Chest·2012
Same author

Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.

Thrombosis and haemostasis·2010

Area of Science:

  • Hematology
  • Genetics
  • Clinical Medicine

Background:

  • Thrombophilias, inherited or acquired, increase thrombosis risk.
  • These conditions can lead to venous thromboembolism and arterial occlusion.
  • Management strategies must account for the heterogeneity of thrombophilias.

Purpose of the Study:

  • To provide guidance on managing patients with thrombophilias.
  • To clarify the role of inherited thrombophilias in anticoagulant therapy duration.
  • To address special considerations for thrombosis in malignancy and antiphospholipid syndrome.

Main Methods:

  • Review of existing literature and clinical trial data.
  • Analysis of risk-benefit balance for extended anticoagulant therapy.
  • Consideration of genetic penetrance and expression in family screening.

Main Results:

  • Inherited thrombophilias do not necessitate altered anticoagulant intensity.
  • Optimal anticoagulant duration depends on individual thrombosis and bleeding risks.
  • Low molecular weight heparins may be more effective for cancer-associated thrombosis.

Conclusions:

  • Individualized risk assessment is crucial for managing thrombophilias.
  • Extended anticoagulant therapy may be beneficial in certain inherited thrombophilias.
  • Family screening for thrombophilias requires careful consideration of consent and genetic factors.

Related Experiment Videos